Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.
Cilostazol inhibits intimal hyperplasia after stent implantation into canine iliac arteries. To determine the antiproliferative effect of this agent, cilostazol or aspirin was randomly given for 6 mo to 36 patients treated with Palmaz-Schatz stent implantation. Initial success was obtained in 34 patients. Repeat angiography was performed in 33 patients, and the complete angiographic data were obtained in 22 lesions of the cilostazol group and in 21 lesions of the aspirin group. The reference diameter and minimal luminal diameter were similar in both groups before and immediately after stent implantation. At follow-up, minimal luminal diameters were significantly greater in the cilostazol group than in the aspirin group (P < 0.001). Late loss and loss index were significantly smaller in the cilostazol group than in the aspirin group (P < 0.001). These results suggest that cilostazol reduces angiographic late lumen loss and thereby may reduce the incidence of restenosis after Palmaz-Schatz stent implantation.
Yamasaki
M
M
Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Hara
K
K
Ikari
Y
Y
Kobayashi
N
N
Kozuma
K
K
Ohmoto
Y
Y
Oh-Hashi
Y
Y
Ako
J
J
Nakajima
H
H
Chiku
N
N
Saeki
F
F
Tamura
T
T
D000368:Aged; D000818:Animals; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D000077407:Cilostazol; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D014654:Vascular Patency / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol; D001241:Aspirin